Johnson & Johnson MedTech company Ethicon has obtained CE mark approval for its adjunctive haemostatic sealing patch, ETHIZIA.
It was approved as an adjunctive haemostat for disruptive bleeding on internal organs, except neurological and cardiovascular.
Featuring synthetic polymer technology, ETHIZIA is claimed to be the first and only haemostatic matrix that is equally productive and active on both sides.
The sealing patch, designed for maximum adaptability, can be stuffed, rolled, pulled apart, trimmed and tailored to handle minimally invasive and open surgeries.
After regulatory approvals, the company plans to launch this sealing patch in EMEA in the first quarter of next year and in other major markets in LATAM, APAC and North America.
Ethicon Company Group chairman Vladimir Makatsaria said: “As a global leader in surgery, we are committed to empowering healthcare providers to safeguard patients from surgical complications by continuously delivering breakthrough solutions.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
“Disruptive bleeding can contribute to serious complications and with the addition of ETHIZIA to our portfolio, we are well positioned to deliver critical haemostasis solutions for patients.”
Ethicon is focused on developing clinically differentiated surgical technologies and solutions to address the health challenges associated with cancer, metabolic disease and cardiovascular disease.
Last year, the company acquired Netherlands-based GATT Technologies, which utilises differentiated synthetic polymers to develop haemostatic and sealant products for solving complex surgical bleeding and leak challenges.
